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MTT assayAbstract In the present study steroidal derivatives, 3b-[50-mercapto-10,30,40-oxadiazole-2-yl]methoxy
cholest-5-ene 2, 3b-[20,50-dimethylpyrrole-1-yl]aminocarbonylmethoxycholest-5-ene 3 and 3b-[30,50-
dimethyl pyrazole-1-yl]carbonylmethoxycholest-5-ene 4 have been synthesized from cholest-5-en-
3b-O-acetyl hydrazide 1 using CS2/KOH, acetonyl acetone and acetyl acetone, respectively as
reagents and are characterized by IR, 1H NMR,13C NMR, MS and elemental analysis. Compounds
2–4 were also evaluated for anticancer activity against human leukemia cell line (HL-60) by MTT
assay and compound 4 displayed the promising behavior by showing better anticancer activity.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
1,3,4-Oxadiazoles, pyrroles, pyrazoles and their derivatives rep-
resent an important class of heterocyclic compounds with
broad spectrum of biological activity. 1,3,4-Oxadiazoles have
been reported to possess insecticidal (Zheng et al., 2003), herbi-
cidal (Chavan et al., 2006), antibacterial (Shivarama Hollaa
et al., 2000), antifungal (Liu et al., 2008), analgesic (Narayana
et al., 2005), anti-inﬂammatory (Koksal et al., 2008), antimalar-
ial (Zareef et al., 2007a), antiviral (Farghaly and El-Kashef,
2006), anti-HBV (El-Essawy et al., 2007), antianxiety (Amr
et al., 2008), anticancer (Kumar et al., 2008), anti-HIV (Zareef
et al., 2007b), antitubercular (Macaev et al., 2005) and anticon-vulsant activities (Zarghi et al., 2005). Substituted pyrroles have
been used as intermediates in the synthesis of mitomycin anti-
tumor antibiotics possessing antibacterial activity (De Leon
and Ganem, 1997; Gilchrist, 1998; Luly and Rapoport, 1983).
Functionalized pyrroles are building blocks of natural tetrapyr-
role pigments (Dutton et al., 1983) such as porphobilinogen or
bilirubin and various other natural products and their analogs
(Shen et al., 1993). Pyrazoles and their derivatives are of much
importance on account of their use in therapy in different dis-
eases (El-Hawash et al., 2006; Salgin-Goksen et al., 2007; Savel-
li and Alessandro, 1996). They are also reported to possess
antibacterial (Abdallah et al., 2005), fungicidal (Devasia
et al., 2006), antidiuretic (Vicini et al., 2002), anticancer (Ros-
tom, 2006; Ibrahim et al., 2007), anti-HIV (Rida et al., 2005;
Salih, 2008), antitumor (Salgin-Goksen et al., 2007), analge-
sic-anti-inﬂammatory (Gulcan et al., 2003; Onkol et al., 2008)
and anticonvulsant (Onkol et al., 2004) properties. This gave
a great impetus to the search for potential pharmacologically
active drugs carrying such moieties.
Taking into consideration the existing cancer therapies,
chemotherapy has turned out to be one of the most signiﬁcant
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natural product based drugs, Paclitaxel and Docetaxel, are
extensively used in the treatment of a wide variety of cancers
because of their efﬁcacy (Carlson, 2008). Researchers are direc-
ted toward the search for anticancer drugs with limited harm-
ful side effects particularly with respect to the immune system.
Prompted by these observations and in continuation of our re-
searches (Shamsuzzaman et al., 2010) on biologically active
heterocycles we hereby report the synthesis of some new substi-
tuted steroidal pyrazole, 1,3,4-oxadiazole and pyrrole deriva-
tives which have also been evaluated for their anticancer
activity against human leukemia cell line.
2. Experimental
2.1. Chemistry
All melting points were recorded in open capillary tube and are
uncorrected. Infrared spectra were recorded in KBr pellets
with spectrolab interspec 2020 FT-IR spectrometer and values
are given in cm1. 1H and 13C NMR spectra were run in
CDCl3 at 300 and 100 MHz, respectively using TMS as an
internal standard and values are given in ppm (d). TLC plates
were coated with silica gel G, light petroleum ether refers to a
fraction of bp. 60–80 C. Anhydrous sodium sulfate was used
as drying agent. The abbreviations s, d, dd, m and br denote
‘‘singlet, doublet, double-doublet, multiplet and broad’’,
respectively.
2.2. 3b-[30,50-Mercapto -10,30,40-oxadiazole-2-yl]methoxycho
lest-5-ene (2)
To a solution of compound 1 (Satyanarayana and Siddiqui,
1994) (1.08 mmol) in absolute ethanol (40 ml), KOH and
CS2 dissolved in absolute ethanol (10 ml) in equimolar
amounts were added and the reaction mixture was heated un-
der reﬂux till the evolution of H2S ceased (21 h.). The reaction
mixture was cooled to room temperature, poured in ice cold
water and neutralized with dil. HCl. The precipitated solid
was ﬁltered, dissolved in diethyl ether, washed with water
and dried over anhydrous Na2SO4. Evaporation of solvent
and recrystallization from ethanol provided compound 2.
Solid; Yield: 67.5%; mp 125–126 C; Anal. Calcd for
C30H48N2O2S: C, 71.92, H, 9.68, N, 5.55. Found C, 71.95,
H, 9.66, N, 5.59; IR (KBr) t cm1: 1625 (C‚N), 1385 (C–
N), 1220 (C–O), 1195 (C‚S); 1H NMR (CDCl3, 300 MHz,
ppm): d 9.06 (br s, 1H, NH, exchangeable with D2O), 5.38
(dd, J= 8 Hz, 4 Hz, 1H, C6-H), 4.6 (m, W1/2, 15 Hz, 1H, ax-
ial, C3a-H), 3.54 (s, 2H, O-CH2), 1.15 (s, 3H, C10-CH3), 0.74 (s,
3H, C13-CH3), 0.90, 0.85 (other steroidal side-chain methyl
protons). 13 C NMR (CDCl3, 100 MHz, ppm) d 156.5, 155.1,
148.9, 122.9, 75.9, 73.7, 48.3, 46.3, 42.78, 40.5, 39.8, 39.40,
35.8, 33.49, 33.2, 32.7, 31.9, 30.3, 29.5, 29.3, 28.7, 25.4, 22.4,
22.2, 21.7, 21.1, 20.8, 20.4, 20.3, 18.6; MS: m/z [M+] 500.
2.3. 3b-[20,50-Dimethylpyrrole-1-yl]aminocarbonylmethoxy
cholest-5-ene (3)
A solution of compound 1 (1.08 mmol) in absolute ethanol
(25 ml) was added to a solution of acetonyl acetone
(1.08 mmol) and 1 N glacial acetic acid (5 ml). The mixture
was heated on a boiling water bath for 7 h. The progress ofreaction was monitored by TLC. After completion, the reac-
tion mixture was concentrated to half of its original volume
and poured in ice cold water (100–150 ml). The separated solid
was ﬁltered, washed with water, air dried and then recrystal-
lized from ethanol to get compound 3.
Solid; yield 69%; mp 131–133 C; Anal. Calcd for
C35H56N2O2: C, 78.31, H, 10.51, N, 5.22. Found C,78.29, H,
10.55, N, 5.20; IR (KBr) t cm1: 1753 (C‚O), 1615 (C‚C),
1340 (C–N), 1196 cm1 (C–O); 1H NMR (CDCl3, 300 MHz,
ppm): d 8.3(s, 1H, NH, exchangeable with D2O), 5.71 (s, 2H,
2 · CH of pyrrole), 5.28 (dd 1H, J= 9 Hz, 5 Hz, C6-H), 2.34
(s, 6H, 2 · CH3), 4.58 (m, 1H, W1/2, 16 Hz, axial, C3a-H),
4.86 (s, 2H, O-CH2), 1.17 (s, 3H, C10-CH3), 0.74 (s, 3H, C13-
CH3), 0.93, 0.84 (other steroidal side-chain methyl protons).
13 C NMR (CDCl3, 100 MHz, ppm) d 173.2, 149.1, 130.3,
130.1, 122.9, 108.2, 108.1, 75.6, 74.5, 48.5, 48.3, 46.5, 42.9,
40.4, 40.3, 39.8, 39.6, 35.8, 33.4, 32.4, 31.7, 30.3, 29.7, 29.6,
28.5, 25.4, 22.5, 22.3, 21.5, 21.3, 20.4, 20.3, 20.2, 18.6, 5.3,
5.1; ESI MS: m/z [M+] 536.
2.4. 3b-[30,50-Dimethyl pyrazole-1-yl]carbonylmethoxycholest-
5-ene (4)
To a solution of compound 1 (1.08 mmol) in glacial acetic acid
(50 ml), a solution of acetyl acetone (1.08 mmol) and 1 N gla-
cial acetic acid (5 ml), in absolute ethanol (40 ml) was slowly
added. The mixture was reﬂuxed at 100–125 C in an oil bath
for 8 h. After the completion (TLC) the reaction mixture was
poured into ice cold water (80–100 ml) and allowed to stand
overnight. The precipitated solid was ﬁltered, taken in diethyl
ether, washed with water, dried over anhydrous sodium sulfate
and recrystallized from ethanol to afford compound 4.
Solid; Yield: 71%; mp 138–141 C; Anal. Calcd for
C34H54N2O2: C, 78.11, H, 10.41, N, 5.36. Found; C, 78.09,
H, 10.33, N, 5.35; IR (KBr) t cm1; 1716 (C‚O), 1624
(C‚N), 1620 (C‚C), 1397 (C–N), 1215, 1089 (C–O); 1H
NMR (CDCl3, 300 MHz, ppm): d 5.6 (dd, J= 7 Hz, 3 Hz,
1H, C6-H), 5.49 (s, 1H, pyrazole ring), 4.82 (m, W1/2, 14 Hz,
axial, 1H, C3a-H), 4.27 (s, 2H, O-CH2-), 1.56 (s, 6H,
2 · CH3 of pyrazole ring), 1.17 (s, 3H, C10-CH3), 0.72 (s, 3H,
C13-CH3), 0.91, 0.83 (other steroidal side-chain methyl pro-
tons). 13 C NMR (CDCl3, 100 MHz, ppm) d 200.3, 149.1,
147.3, 147.2, 122.9, 106.1, 74.8, 67.8, 48.5, 46.4, 42.9, 40.6,
39.8, 39.7, 39.4, 35.8, 32.7, 32.5, 31.9, 30.3, 29.6, 29.5, 28.6,
25.4, 22.5, 22.4, 21.7, 21.3, 20.9, 20.5, 20.3, 18.6, 13.7, 7.3;
ESI MS: m/z [M+] 522.
2.5. Anticancer activity
2.5.1. Cell lines and culture conditions
Human cancer cell line HL-60 cells were grown in RPMI 1640
supplemented with 10% fetal bovine serum (FBS), 10U peni-
cillin and 100 lg/ml streptomycin at 37 C with 5% CO2 in a
humidiﬁed atmosphere. Fresh medium was given every second
day and on the day before the experiments were done. Cells
were passaged at preconﬂuent densities, using a solution con-
taining 0.05% trypsin and 0.5 mM EDTA.
2.5.2. Cell viability assay (MTT)
The anticancer activity in vitro was measured using the MTT
assay. The assay was carried out according to known protocol
(Slater et al., 1963; Van de Loosdrecht et al., 1994). Exponen-
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at a concentration of 1 · 104 cells/well. After 24 h incubation
at 37 C under humidiﬁed 5% CO2 to allow cell attachment,
the cells in the wells were, respectively, treated with target com-
pounds at various concentrations for 48 h. The concentration
of DMSO was always kept below 1.25%, which was found
to be non-toxic to the cells. A solution of 3-(4,5-dimethylth-
izao1-2-y1)-2,5-diphenyltetrazolium bromide (MTT), was pre-
pared at 5 mg/ml in phosphate buffered saline (PBS; 1.5 mM
KH2PO4, 6.5 mM Na2HPO4, 137 mM NaCl, 2.7 mM KCl;
pH 7.4). Of this solution 20 ll was added to each well. After
incubation for 4 h at 37 C in a humidiﬁed incubator with
5% CO2, the medium/MTT mixtures were removed, and the
formazan crystals formed by the mitochondrial dehydrogenase
activity of vital cells were dissolved in 100 ll of DMSO per
well. The absorbance of the wells was read with a microplate
reader (Bio-Rad Instruments) at 570 nm. Effects of the drug
cell viability were calculated using cells treated with DMSO
as control.
2.5.3. Data analysis
Cell survival was calculated using the formula: Survival
(%) = [(absorbance of treated cellsabsorbance of culture
medium)/(absorbance of untreated cellsabsorbance of culture
medium)] · 100 (Woerdenbag et al., 1993). The experiment was
done in triplicate and the inhibitory concentration (IC) values
were calculated from a dose response curve. IC50 is the concen-
tration in ‘lM’ required for 50% inhibition of cell growth as
compared to that of untreated control. IC50 values were deter-
mined from the linear portion of the curve by calculating the
concentration of agent that reduced absorbance in treated cells,
compared to control cells, by 50%. Evaluation is based on
mean values from three independent experiments, each com-
prising at least six microcultures per concentration level.
3. Results and discussion
3.1. Chemistry
Newly synthesized compounds 3b-[50-mercapto-10,30,40-oxadi-
azole-2-yl] methoxycholest-5-ene 2, 3b-[20,50-dimethyl pyrrole-
1-yl] aminocarbonyl methoxy cholest-5-ene 3 and 3b-[30,
50-dimethylpyrazole-1-yl]carbonylmethoxycholest-5-ene 4 were
synthesized from cholesten-5-en-3b-O-acetylhydrazide 1.
Compound 1 in turn was synthesized from ethyl-5-cholesten-
3b-O-acetate B (Satyanarayana and Siddiqui, 1994). The tar-
geted steroidal derivatives 2–4 were obtained with CS2/KOH,
acetonyl acetone and acetyl acetone, respectively. The reaction
pathway has been summarized in Scheme 1. The synthesized
compounds 2–4 were characterized by IR, NMR, MS and ele-
mental analyses.
The selected indicative bands in IR spectra of targeted com-
pounds 2–4 provide useful information for determining their
structures. The IR spectrum of steroidal 1,3,4-oxadiazole 2
exhibited characteristic absorption bands at 1625 (C‚N),
1385 (C–N), 1220 (C–O) and 1195 cm1 (C‚S). In the IR
spectrum of steroidal pyrrole 3 characteristic absorption bands
at 1753, 1615, 1340 and 1196 cm1 were due to C‚O, C‚C,
C–N and C–O groups, respectively. Similarly the IR spectrum
of steroidal pyrazole 4 showed absorption bands at 1716
(C‚O), 1624 (C‚N), 1620 (C‚C), 1397 (C–N), 1215 and
1089 cm1 (C–O).The structures of compounds 2–4 were also supported by
the study of their 1H NMR spectra. The 1H NMR spectrum
of compound 2 displayed a single proton singlet at d 9.06
(exchangeable with D2O) for NH of oxadiazole ring, a two-
proton singlet at d 3.54 (O-CH2–), a double-doublet for a sin-
gle proton at d 5.38 (J= 8 Hz, 4 Hz) for C6-H, and a one-pro-
ton broad multiplet centered at d 4.6 (W1/2, 15 Hz, axial) for
C3a-H. Steroidal pyrrole 3 in its
1H NMR spectrum showed a
singlet for one-proton at d 8.3 (–NH, exchangeable with D2O),
two oleﬁnic protons of pyrrole ring at d 5.71, a double-doublet
for a single proton at d 5.28 (J= 9 Hz, 5 Hz, C6-H), a one-
proton broad multiplet centered at d 4.58 (W1/2, 16 Hz, axial)
for C3a-H and another singlet for two-protons at d 4.86
(OCH2). Six methyl protons of pyrrole ring appeared as singlet
at d 2.34. In the 1H NMR spectrum of compound 4, two ole-
ﬁnic protons appeared separately at d 5.6 (J= 7 Hz, 3 Hz, C6-
H) and 5.49 (pyrazole ring) as a double-doublet and a singlet,
respectively. It also showed a two-proton singlet at d 4.72 for
OCH2, another singlet for six protons (2 · CH3) at 1.56
and a broad multiplet integrating for one-proton at d 4.82
(W1/2, 14 Hz, axial) for C3a-H. Other prominent peaks of
steroidal nucleus in the compounds 2–4 were observed at
their characteristic positions and are given in experimental
section.
13C NMR spectra of compounds 2–4 were in good agree-
ment with the proposed structures. The presence of the 1,3,
4-oxadiazole unit in compound 2 was supported by the appear-
ance of two quaternary signals (C20 and C50 ) in the range d
156.5–155.1 in the 13C NMR spectrum. The methylene carbon
attached to oxadiazole moiety appeared at d 73.7. Similarly the
structure of pyrrole 3 was also conﬁrmed by the 13C NMR
which displayed signals at d 130.1–130.3 for C20 and C50 of pyr-
role ring and d 108.2–108.1 for C30 and C40 of pyrrole ring. The
two methyl carbons attached at C20 and C50 of pyrrole ring are
also found to appear at d 5.1–5.3. Other important signals ap-
peared at d 173.2 and 74.5 for –NHCO and for –OCH2, respec-
tively. In the 13C NMR spectrum of compound 4 the carbonyl
and methylene carbons appeared at d 200.3 and 67.8, respec-
tively. The carbons of pyrazole moiety appeared at d 149.1
(C30 ), 106.1 (C40 ), 147.3 (C50 ) and 7.3–13.7 (2 · CH3). Other
characteristic peaks of 13C NMR for compounds 2–4 are given
in the experimental section.
In ESI mass analysis the distinctive signals were observed in
the mass spectra of compounds 2–4 which followed the deﬁnite
fragmentation pattern. The molecular ion peaks (M+) for
compounds 2–4 were observed at m/z 500, 536 and 522,
respectively.
3.2. Anticancer activity
In vitro evaluation of anticancer activity of the synthesized
compounds was carried out using the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Slater
et al., 1963). The conversion of the soluble yellowish MTT
to the insoluble purple formazan by active mitochondrial lac-
tate dehydrogenase of living cells has been used to develop an
assay system for measurement of cell proliferation. Cell viabil-
ity was measured with the purple formazan that was metabo-
lized from MTT mitochondrial lactate dehydrogenase, which
is active only in live cells. The screening of compounds 2–4
was done using the human leukemia cell line. Anticancer po-
tency of the compounds was indicated by IC50 values that were
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Scheme 1 Formation of steroidal oxadiazole, pyrrole and pyrazole.
390 Shamsuzzaman et al.calculated by linear regression analysis of the concentration-re-
sponse curves obtained for each compound. Anticancer study
showed that compound 4 was most active toward HL-60 cells
among the three compounds with IC50 = 14.32 while the IC50
for compounds 2 and 3 were 17.33 and 18.57, respectively. It
may be inferred that compound 4 contains ‘[30,50-dimethylpyr-
azole-1-yl] carbonylmethoxy’ moiety attached at 3b position
which may be responsible for this enhanced anticancer activity.
4. Conclusion
The present work involves the simple and convenient synthesis
of steroidal 1,3,4-oxadiazole, pyrrole and pyrazole 2–4 in rea-
sonably good yields. This strategy offered a very straightfor-
ward and efﬁcient method to access steroidal 1,3,4-
oxadiazole, pyrrole and pyrazole. The products 2–4 after being
characterized by IR, 1H NMR, 13C NMR, MS and elemental
analysis, were screened for anticancer study against HL-60 cell
line during which compound 4 has been identiﬁed more prom-
ising by showing better anticancer behavior (IC50 = 14.32).
Compounds 2 and 3 also showed moderate to good anticancer
activity by showing IC50 = 17.33 and 18.57, respectively. This
study also supports that pyrazole moiety after being attached
with steroidal nucleus may be the factor responsible for en-
hanced anticancer behavior as pyrazoles are being considered
better anticancer agents (Rostom, 2006; Ibrahim et al.,
2007). In conclusion the present study showed that the synthe-
sized compounds can be used as templates for future develop-ment through modiﬁcation and derivatization to design more
potent and selective anticancer agents.Acknowledgments
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